Dennis J. Selkoe

Academic and clinical career

Selkoe joined the faculty of Harvard Medical School in 1975 as Instructor in Neurology, later becoming a professor of neurology and neuroscience. In 1985, he co-founded and became co-director of the Center for Neurologic Diseases at Brigham and women's Hospital, and in 1990 he received an endowed chair as the Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School. He has held clinical appointments at Brigham and Women's Hospital and Massachusetts General Hospital, where he has practiced neurology while directing a laboratory focused on neurodegenerative disease research, principally Alzheimer's and Parkinson's diseases.

He was the principal founding scientist of the biotechnology company Athena Neurosciences in 1986. Subsequently, he served on the boards of the biotech companies Athena, Elan, and Prothena. Selkoe also co-founded the Harvard Center for Neurodegeneration and Repair in 2001, reflecting his involvement in translational research initiatives aimed at developing therapies for neurologic diseases.

Research

Alzheimer's disease mechanisms

Selkoe's laboratory identified amyloid-β (Aβ) peptides as pathogenic agents in AD and showed that these peptides are produced naturally throughout life from the amyloid precursor protein (APP) in essentially all cells. He and collaborators demonstrated that mutations in APP and later in the presenilin genes increase the production and accumulation of the toxic Aβ42 peptide and cause familial, early-onset Alzheimer's disease, establishing a genetic link between APP processing and neurodegeneration. In 1999, Selkoe's group identified presenilin as the catalytic component of the γ-secretase complex, the enzyme responsible for processing APP into Aβ throughout life, advancing understanding of pathogenic events in brain aging and AD.

Amyloid cascade hypothesis and synaptic toxicity

Selkoe contributed to the formulation and refinement of the amyloid cascade hypothesis, which proposes that accumulation and misprocessing of Aβ is an early driver of AD pathology, triggering downstream processes including tau pathology, synaptic dysfunction, and cognitive decline. His laboratory also provided evidence that soluble Aβ oligomers, rather than insoluble plaques alone, can impair synaptic function and memory, linking specific molecular abnormalities to cognitive deficits. He proposed that an imbalance in Aβ production and clearance, particularly increased levels of Aβ42, plays a central role in initiating AD pathology long before its clinical symptoms appear.

Broader neurodegenerative mechanisms

Selkoe's research extends to protein misfolding and aggregation in other neurodegenerative disorders, including Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, exploring partly shared pathways of cytotoxicity and abnormal protein clearance. His work examines the interplay between misfolded proteins, synaptic dysfunction, cellular stress responses, inflammation, and neuronal death, contributing to a systems-level understanding of neurodegeneration.

Therapeutic insights and translational impact

Selkoe has also published perspectives on how emerging Alzheimer's treatments could fundamentally alter the trajectory of human aging and dementia.